



ASX Release

15 August 2016

Medlab Clinical Limited Pro Rata Rights Issue RESULTS AND NOTIFICATION OF SHORTFALL

Medlab Clinical Limited (ASX: MDC) announces that its fully underwritten renounceable pro-rata rights issue (**the Rights Issue**) to raise approximately \$5,361,150.00 (before costs) pursuant to the Offer Document dated 18 July 2016, closed on 9 August 2016.

Under the Rights issue, eligible shareholders with a registered address in Australia, New Zealand, Hong Kong or Singapore were entitled to subscribe for one new fully paid ordinary share for every nine shares held as at the Record Date at an issue price of \$0.30 each. The Rights issue was fully underwritten by a shareholder of the Company, Farjoy Pty Ltd as detailed in the Offer Document lodged with the ASX.

The Company received applications under the Rights Issue for eligible shareholders in respect of 11,758,039 new shares. Eligible shareholders were also granted 2,898,451 additional shares in excess of their respective entitlements under the Top-Up Offer. Total funds raised from accepted applications were \$4,396,947.

The remaining shares under the Shortfall, being 3,214,010 shares will be taken up by the Underwriter to the Rights Issue and will be issued in accordance with the underwriting agreement.

Total funds to be raised from accepted applications from eligible shareholders and shares issued to the Underwriter will total \$5,361,150 (before costs).

The allotment for New Shares and Shortfall shares to be issued to Shareholders will be issued on the 16 August. Settlement of any Shortfall Shares to be issued to the Underwriter is scheduled to take place on 30 August 2016.

For and on behalf of the board of the Company.

Alan Dworkin
Company Secretary
Medlab Clinical Ltd